120 related articles for article (PubMed ID: 15254732)
1. In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
Saiko P; Horvath Z; Bauer W; Hoechtl T; Grusch M; Krupitza G; Rauko P; Mader RM; Jaeger W; Schott H; Novotny L; Fritzer-Szekeres M; Szekeres T
Int J Oncol; 2004 Aug; 25(2):357-64. PubMed ID: 15254732
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic and apoptotic effects of novel heterodinucleoside phosphates consisting of 5-fluorodeoxyuridine and Ara-C in human cancer cell lines.
Saiko P; Bauer W; Horvath Z; Hoechtl T; Grusch M; Illmer C; Madlener S; Krupitza G; Mader RM; Schott H; Fritzer-Szekeres M; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1507-11. PubMed ID: 15571287
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells.
Saiko P; Horvath Z; Illmer C; Madlener S; Bauer W; Hoechtl T; Erlach N; Grusch M; Krupitza G; Mader RM; Jaeger W; Schott H; Agarwal RP; Fritzer-Szekeres M; Szekeres T
Leuk Res; 2005 Jul; 29(7):785-91. PubMed ID: 15927674
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
Rauko P; Novotny L; Mego M; Saiko P; Schott H; Szekeres T
Neoplasma; 2007; 54(1):68-74. PubMed ID: 17203895
[TBL] [Abstract][Full Text] [Related]
5. Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine--new drugs in cancer chemotherapy?
Saiko P; Horvath Z; Jaeger W; Schott H; Fritzer-Szekeres M; Szekeres T
In Vivo; 2005; 19(1):205-14. PubMed ID: 15796176
[TBL] [Abstract][Full Text] [Related]
6. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
[TBL] [Abstract][Full Text] [Related]
9. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
10. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
11. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Strasser S; Maier S; Leisser C; Saiko P; Madlener S; Bader Y; Bernhaus A; Gueorguieva M; Richter S; Mader RM; Wesierska-Gadek J; Schott H; Szekeres T; Fritzer-Szekeres M; Krupitza G
Differentiation; 2006 Dec; 74(9-10):488-98. PubMed ID: 17177846
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
15. Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis.
Saiko P; Ozsvar-Kozma M; Graser G; Lackner A; Grusch M; Madlener S; Krupitza G; Jaeger W; Hidvegi M; Agarwal RP; Fritzer-Szekeres M; Szekeres T
Oncol Rep; 2009 Mar; 21(3):787-91. PubMed ID: 19212640
[TBL] [Abstract][Full Text] [Related]
16. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of action of 5-FU: biochemical basis.
Rustum YM; Danhauser L; Wang G
Bull Cancer; 1979; 66(1):43-7. PubMed ID: 154352
[TBL] [Abstract][Full Text] [Related]
19. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
20. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
